Loading...
XCSE
HLUN A
Market cap3.87bUSD
Apr 02, Last price  
27.35DKK
1D
-2.50%
1Q
-21.07%
Name

H. Lundbeck

Chart & Performance

D1W1MN
P/E
8.47
P/S
1.21
EPS
3.23
Div Yield, %
2.56%
Shrs. gr., 5y
4.52%
Rev. gr., 5y
4.86%
Revenues
22.00b
+10.51%
9,069,800,0009,221,000,00010,984,900,00011,281,800,00013,747,000,00014,765,000,00016,007,000,00014,802,000,00015,258,000,00013,468,000,00014,594,000,00015,634,000,00017,234,000,00017,875,000,00017,358,000,00017,667,000,00016,299,000,00018,246,000,00019,912,000,00022,004,000,000
Net income
3.14b
+37.25%
2,923,400,0002,158,700,0003,353,500,0002,736,200,0002,007,000,0002,466,000,0002,282,000,0001,107,000,000855,000,000-153,000,000-5,694,000,0001,211,000,0002,624,000,0003,907,000,0002,667,000,0001,581,000,0001,318,000,0001,916,000,0002,290,000,0003,143,000,000
CFO
3.33b
-18.48%
2,071,500,0001,394,000,0002,704,800,0002,780,200,0003,034,000,0003,265,000,0003,624,000,0002,112,000,0003,760,000,0001,610,000,000197,000,0003,126,000,0004,045,000,0005,981,000,0002,609,000,0003,837,000,0002,272,000,0003,519,000,0004,080,000,0003,326,000,000
Dividend
Mar 21, 20240.7 DKK/sh

Profile

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
URL
https://www.lundbeck.com/
IPO date
Jan 01, 1999
Employees
5,600
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
22,004,000
10.51%
19,912,000
9.13%
18,246,000
11.95%
Cost of revenue
18,314,000
16,717,000
15,394,000
Unusual Expense (Income)
NOPBT
3,690,000
3,195,000
2,852,000
NOPBT Margin
16.77%
16.05%
15.63%
Operating Taxes
576,000
703,000
558,000
Tax Rate
15.61%
22.00%
19.57%
NOPAT
3,114,000
2,492,000
2,294,000
Net income
3,143,000
37.25%
2,290,000
19.52%
1,916,000
45.37%
Dividends
(694,000)
(576,000)
(397,000)
Dividend yield
2.10%
2.02%
1.67%
Proceeds from repurchase of equity
(46,000)
(43,000)
(45,000)
BB yield
0.14%
0.15%
0.19%
Debt
Debt current
82,000
86,000
88,000
Long-term debt
17,130,000
4,502,000
5,974,000
Deferred revenue
Other long-term liabilities
1,245,000
1,024,000
831,000
Net debt
12,548,000
(422,000)
2,273,000
Cash flow
Cash from operating activities
3,326,000
4,080,000
3,519,000
CAPEX
(508,000)
(277,000)
(820,000)
Cash from investing activities
(15,286,000)
(498,000)
(1,892,000)
Cash from financing activities
11,629,000
(2,085,000)
(387,000)
FCF
2,649,000
5,996,000
(1,304,000)
Balance
Cash
4,664,000
5,010,000
3,421,000
Long term investments
368,000
Excess cash
3,563,800
4,014,400
2,876,700
Stockholders' equity
23,330,000
22,045,000
20,779,000
Invested Capital
39,384,200
23,205,600
23,777,300
ROIC
9.95%
10.61%
9.96%
ROCE
7.61%
10.83%
9.90%
EV
Common stock shares outstanding
991,438
992,235
992,867
Price
33.40
16.38%
28.70
20.18%
23.88
 
Market cap
33,114,029
16.28%
28,477,144
20.11%
23,709,664
 
EV
45,662,029
28,055,144
25,982,664
EBITDA
5,566,000
5,207,000
4,663,000
EV/EBITDA
8.20
5.39
5.57
Interest
113,000
97,000
103,000
Interest/NOPBT
3.06%
3.04%
3.61%